Impact News +++ PRODWAYS : 2020 revenue impacted by the health crisis, recovery forecast in 2021 (Actusnews) +++ PRODWAYS Aktie +3,69%

OTONOMY Aktie

 >OTONOMY Aktienkurs 
2.50 EUR    +5.2%    (Tradegate)
Ask: 2.51 EUR / 1600 Stück
Bid: 2.46 EUR / 1600 Stück
Tagesumsatz: 9608 Stück
Realtime Kurs von 8 bis 22 Uhr!
>OTONOMY Performance
1 Woche: -42,6%
1 Monat: -40,1%
3 Monate: -34,6%
6 Monate: -35,6%
1 Jahr: -27,0%
laufendes Jahr: -49,9%
>OTONOMY Aktie
Name:  OTONOMY INC. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US68906L1052 / A119VZ
Symbol/ Ticker:  7OT (Frankfurt) / OTIC (NASDAQ)
Kürzel:  FRA:7OT, 7OT.F, 7OT:GR, NASDAQ:OTIC
Index:  -
Webseite:  https://www.otonomy.com/
Marktkapitalisierung:  215.39 Mio. EUR
Umsatz:  0.23 Mio. EUR
EBITDA:  -34.99 Mio. EUR
Gewinn je Aktie:  -0.903 EUR
Schulden:  26.62 Mio. EUR
Liquide Mittel:  71.22 Mio. EUR
Umsatz-/ Gewinnwachstum:  -43% / -
KGV/ KGV lG:  - / -2.88
KUV/ KBV/ PEG:  788.99 / 3.29 / -0.25
Gewinnm./ Eigenkapitalr.:  - / -84%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  OTONOMY
Letzte Datenerhebung:  24.02.21
>OTONOMY Eigentümer
Aktien: 48.32 Mio. St.
f.h. Aktien: 39.73 Mio. St.
Insider Eigner: 0.25%
Instit. Eigner: 77.21%
Leerverk. Aktien: 3.21%
>OTONOMY Peer Group

 
24.02.21 - 10:57
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:54
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:48
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:45
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:42
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:39
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:36
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:30
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:27
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:24
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:21
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:18
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:15
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:12
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:06
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 10:00
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 09:57
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 09:54
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 09:51
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
24.02.21 - 09:48
BCLI Slips On FDA Feedback, OTIC Plunges As Ménière′s Disease Trial Fails, CLNN On Watch (RTTNews)
 
Today's Daily Dose brings you news about disappointing results from Otonomy's phase III trial of OTIVIDEX in Ménière's disease, FDA'S feedback related to BrainStorm's NurOwn cell therapy, Fast Track designation for Celsion's ovarian cancer dr...
>Zitat des Tages: Es ist nötig, alle seine Kenntnisse umzurühren und sie dann wieder setzen zu lassen, um zu sehen, wie sich alles setzt. - Georg Christoph Lichtenberg
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!